Ohnesorge H, Alpes A, Baron R, Gierthmühlen J
a Department of Anaesthesiology and Intensive Care Medicine , University Hospital Schleswig-Holstein , Campus Kiel , Kiel , Germany.
b Division of Neurological Pain Research and Therapy, Department of Neurology , University Hospital Schleswig-Holstein , Campus Kiel , Kiel , Germany.
Curr Med Res Opin. 2016 Nov;32(11):1797-1805. doi: 10.1080/03007995.2016.1211517. Epub 2016 Aug 1.
The clinical relevance of pro- and hyperalgesic effects of opioids is still a matter of debate. Particularly for remifentanil, an increased postoperative need for analgesics has been demonstrated suggesting opioid-induced hyperalgesia as a possible cause. The aim of the study was therefore to investigate the effect of intraoperatively applied remifentanil compared to sufentanil on somatosensory thresholds investigated with the quantitative sensory testing (QST) battery of the German Research Network on Neuropathic Pain (DFNS).
Twenty-three patients undergoing surgery of the female breast were randomly assigned to intraoperative remifentanil (0.4 μg × kg × min) or sufentanil (0.25 μg × kg bolus, 0.15 μg × kg, repetition after 60 min) application. Anesthesia was maintained BIS-guided (Bispectral index) with propofol and postoperative analgesia was ensured with paracetamol (max. 3 g/24 h). Quantitative sensory testing was performed in the region of dermatome Th 5 in the mid-axillary line preoperatively and 20 h postoperatively.
The study was registered at the German registry for clinical studies (DRKS00009002).
Comparison of somatosensory thresholds before versus after surgery and application of intraoperative remifentanil or sufentanil.
Sixteen patients could be finally included in the analysis. No differences of mechanical or thermal detection or pain thresholds were observed between pre- and postoperative testing or between remifentanil and sufentanil.
A change of somatosensory thresholds or a clinically relevant opioid-induced hyperalgesia in the selected small patient sample (segmental resections or mastectomy with or without sentinel lymph node biopsy, surgery length <90 minutes, sufficient postoperative pain medication with paracetamol due to rather low postoperative pain intensities) with remifentanil or sufentanil was not detected 20 h after surgery.
阿片类药物的促痛和痛觉过敏效应的临床相关性仍存在争议。特别是瑞芬太尼,已证实术后镇痛需求增加,提示阿片类药物诱导的痛觉过敏可能是一个原因。因此,本研究的目的是通过德国神经病理性疼痛研究网络(DFNS)的定量感觉测试(QST)电池,研究术中应用瑞芬太尼与舒芬太尼相比对体感阈值的影响。
23例接受女性乳房手术的患者被随机分配接受术中瑞芬太尼(0.4μg×kg×min)或舒芬太尼(0.25μg×kg推注,0.15μg×kg,60分钟后重复)应用。麻醉采用丙泊酚双谱指数(BIS)引导维持,术后用对乙酰氨基酚(最大3g/24h)确保镇痛。术前和术后20小时在腋中线第5皮节区域进行定量感觉测试。
该研究已在德国临床研究注册中心(DRKS00009002)注册。
比较手术前后以及术中应用瑞芬太尼或舒芬太尼后的体感阈值。
最终16例患者纳入分析。术前和术后测试之间或瑞芬太尼与舒芬太尼之间,未观察到机械或热觉检测阈值及疼痛阈值的差异。
在选定的小患者样本(节段性切除或乳房切除术,有或无前哨淋巴结活检,手术时间<90分钟,由于术后疼痛强度较低,术后用对乙酰氨基酚充分镇痛)中,术后20小时未检测到瑞芬太尼或舒芬太尼导致的体感阈值变化或临床相关的阿片类药物诱导的痛觉过敏。